CTS (CTS) just closed out FY 2025 with fourth quarter revenue of US$137.3 million and basic EPS of US$0.68, capping a trailing twelve month run of US$541.3 million in revenue and EPS of US$2.21 that has supported 12.4% earnings growth over the past year. Over the last few quarters, revenue has moved from US$127.4 million in Q4 2024 to US$137.3 million in Q4 2025, while quarterly EPS has shifted from US$0.45 to US$0.68, against a backdrop of net margins stepping up from 11.3% to 12.1%. Investors are likely to focus on this as they weigh the durability of the current profitability trend.

With the latest results on the table, the next step is to see how these margin and earnings trends line up with the widely followed narratives around CTS and where those stories might be challenged by the numbers.

Net income and margins quietly do the heavy lifting

• Q4 net income came in at US$19.7 million on US$137.3 million of revenue, compared with US$13.6 million on US$127.4 million a year earlier, while trailing net profit margin for the last 12 months sits at 12.1% versus 11.3% in the prior year period.
• Analysts' consensus view links margin strength to CTS moving up the value chain and expanding into areas like aerospace or defense and higher value medical and industrial applications. However, the modest year over year margin gain from 11.3% to 12.1% suggests:
  • Operational improvements and mix shift are showing up in the numbers, but the pace of margin change over the last year is more measured than the long term growth story around premium offerings might suggest.
  • Claims about a strong pipeline and backlog helping margins are consistent with a 12.1% net margin today, but investors still have to weigh that against exposure to weaker segments such as transportation and uneven medical demand that are also highlighted in the narrative.

If you want to see how this margin story fits into the bigger picture that bulls are talking about, check out the detailed case for CTS in 🐂 CTS Bull Case

Earnings growth slows versus five year pace

• Over the past five years, earnings grew 27.5% per year on average, while the last 12 months delivered 12.4% earnings growth, so the most recent year is running below that longer trend even though trailing EPS for the last 12 months is US$2.21.
• Critics highlight that growth drivers are not all pulling in the same direction, and the data lined up with the bearish narrative shows why:
  • Broad based issues like weak transportation sales and softer diagnostic ultrasound bookings sit alongside the slower 12.4% recent earnings growth rate, which is well under the 27.5% five year average that bulls often point to.
  • Forecasts in the data call for earnings growth of about 7.5% per year and revenue growth of about 4.3% per year, and those slower forward numbers are consistent with bears focusing on growth reliability rather than only the strong history.

Skeptical investors are paying close attention to these slower growth numbers, so it can be useful to see the full cautious case set out in 🐻 CTS Bear Case

Mixed signals from P/E and DCF value

• CTS trades on a trailing P/E of 25.5x at a share price of US$57.29, which is below the US Electronic industry average of 27.8x and well below the peer average of 80.4x, while the DCF fair value in the data is US$45.29.
• Consensus narrative notes that revenue and earnings are still expected to grow, but not as quickly as the broader US market, and the valuation numbers underline that tension:
  • Forecast revenue growth of about 4.3% per year and earnings growth of about 7.5% per year help explain why the P/E can screen lower than industry and peers, even as the DCF fair value sits below the current share price.
  • The gap between the US$45.29 DCF fair value and the US$57.29 share price sits alongside an earnings record that improved margins from 11.3% to 12.1%, and together these data points frame the trade off between CTS's profit profile and what is currently implied by the market.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CTS on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See the numbers differently? Take a couple of minutes to test your own view against the data and shape a clear story for CTS, then Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding CTS.

See What Else Is Out There

CTS pairs a slower 12.4% earnings growth rate with a share price above its US$45.29 DCF fair value, which raises questions about value.

If that mix of tempered growth and a price above fair value makes you cautious, take a few minutes to scan 51 high quality undervalued stocks that may better fit your return expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.